FDA Grants Orphan Drug Designation to Pegrizeprument for Liver Transplant Rejection Prevention
核心洞察
The FDA has granted Orphan Drug Designation to pegrizeprument (搜索) (VEL-101), a novel pegylated monoclonal antibody fragment being developed to prevent organ rejection in liver transplant patients.
Pegrizeprument (搜索) works through a dual mechanism by blocking CD28 (搜索)-mediated T cell activation while preserving CTLA-4 (搜索) immunosuppressive functions, offering a potentially innovative approach to transplant immunosuppression.
The designation highlights the significant unmet medical need for liver transplant recipients who require lifelong immunosuppression with current therapies often associated with complex dosing and toxicities.
Veloxis Pharmaceuticals (搜索) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to pegrizeprument (搜索) (VEL-101) for prevention of organ rejection in patients receiving liver transplants. The designation represents a critical regulatory milestone for the novel investigational immunosuppressive agent and underscores the significant unmet medical need in orthotopic liver transplantation.
Addressing Critical Unmet Need in Liver Transplantation
Liver transplantation serves as a life-saving treatment for patients with acute liver failure, chronic liver failure, or primary hepatic malignancy. However, current treatment approaches present substantial challenges for patients and clinicians alike. Orthotopic liver transplant patients require lifelong immunosuppression, which is often associated with complex dosing regimens and comorbid toxicities.
Despite advancements in post-transplant clinical care, complications from immunosuppression and allograft rejection continue to negatively impact both graft and patient survival. This creates a significant unmet need for new therapies that can address these complications while maintaining adequate immunosuppression.
"We are pleased by the FDA's decision, which highlights the need for groundbreaking therapies to improve outcomes for liver transplant recipients," said Stacy Wheeler, CEO of Veloxis. "This Orphan Drug Designation represents an important step forward for pegrizeprument (搜索) and reinforces Veloxis' commitment to advancing research and developing innovative therapies that improve the lives of transplant patients."
Novel Dual Mechanism of Action
Pegrizeprument (搜索) represents a novel approach to transplant immunosuppression through its unique mechanism of action. The drug is a pegylated monoclonal antibody fragment that binds to and blocks CD28 (搜索)-mediated effector-T cell costimulation, while crucially not blocking CTLA-4 (搜索), an important protein found on T cells that naturally helps keep the body's immune responses in check.
This selective targeting is expected to provide a dual mechanism of action. Directly, pegrizeprument (搜索) blocks CD28 (搜索)-mediated T cell activation, while indirectly, it allows for CTLA-4 (搜索) mediated immunosuppressive functions to continue operating. This approach may offer advantages over current immunosuppressive regimens by providing effective rejection prevention while potentially reducing associated toxicities.
Development Partnership and Regulatory Pathway
Pegrizeprument (搜索), also known as VEL-101 and FR104, was originally discovered and developed by OSE Immunotherapeutics before being licensed to Veloxis Pharmaceuticals (搜索) in April 2021. Under the licensing agreement, Veloxis obtained worldwide rights to develop, manufacture, and commercialize pegrizeprument for all transplant indications.
"This designation underscores the need for better options in solid organ transplantation and marks an important step in pegrizeprument (搜索)'s development. We congratulate Veloxis on this achievement, which highlights the promise of this innovative therapeutic approach," said Sonya Montgomery, Chief Development Officer at OSE Immunotherapeutics.
The FDA Orphan Drug Designation program grants orphan status to investigational drugs and biologics that aim to prevent, diagnose, or treat rare diseases and medical conditions affecting fewer than 200,000 people in the United States. This designation encourages development of treatments for patients with rare diseases whose conditions are traditionally undertreated.
Broader Transplant Development Program
While the current Orphan Drug Designation specifically covers liver transplant rejection prevention, pegrizeprument (搜索) is being developed more broadly for prevention of acute rejection in solid organ transplant recipients. The drug is currently being studied for kidney transplant rejection prevention in clinical trial NCT07290777.
Veloxis Pharmaceuticals (搜索), a global specialty pharmaceutical company and part of Asahi Kasei Corporation (搜索), continues to research how pegrizeprument (搜索) may address unmet needs across the solid organ transplantation population. The company is focused on the global development and commercialization of medications utilized by transplant patients and those with serious related diseases.